GRAND PHARMA (00512): Globally Innovative Nebulized Inhalant GPN01564 for the Treatment of Respiratory Syncytial Virus Approved to Initiate Phase I Clinical Study

date
19:29 19/11/2026
avatar
GMT Eight
GRAND PHARMA (00512) announced that GPN01564, a globally innovative nebulized inhalant independently developed by the Group for the treatment of respiratory syncytial virus (RSV), has been approved by the National Medical Products Administration (NMPA) of the People's Republic of China to initiate a Phase I clinical study. This marks another significant milestone for the Group in the anti-infection direction within the respiratory and critical care field.
GRAND PHARMA (00512) announced that GPN01564, a globally innovative nebulized inhalant independently developed by the Group for the treatment of respiratory syncytial virus (RSV), has been approved by the National Medical Products Administration (NMPA) of the People's Republic of China to initiate Phase I clinical studies. This marks another major milestone for the Group in the anti-infection direction within the respiratory and critical care field. GPN01564 is an RSV fusion protein (F protein) inhibitor. The F protein is a class I membrane fusion protein and, owing to its unique antigenic epitope conformation in the pre-fusion state and its potent ability to induce neutralizing antibodies, has become one of the most promising targets in the field of RSV prevention and treatment research. At the same time, leveraging the nebulized inhalation route, this product requires no systemic administration and delivers the drug directly to the lungs, achieving precise and non-invasive drug delivery, which can improve the medication experience and create a distinct clinical advantage in terms of administration compliance. Preclinical study results show that GPN01564 has good druggability, safety and efficacy. RSV is one of the main pathogens causing lower respiratory tract infections. Although people of any age may be infected with RSV, the disease is usually more severe in infants, especially premature infants, children with chronic lung disease or congenital heart disease (CHD), and the elderly. According to statistics, in 2019, 33 million people worldwide suffered from acute lower respiratory tract infections (ALRTIs) caused by RSV; RSV causes more than 3.6 million hospitalizations of children under 5 years of age each year, of which about 100,000 result in death. China is one of the countries with the highest number of RSV infection cases globally. In 2019, there were approximately 3.5 million cases of ALRTIs caused by RSV among children under 5 years of age in China, accounting for more than 10% of the global total, with 620,000 to 950,000 hospitalizations, accounting for 17% to 24% of the global total and ranking second worldwide. Currently, for RSV infection, only monoclonal antibodies and vaccines are available for the prevention of infection in infants and the elderly. According to the Expert Consensus on the Medical-Preventive Coordination for the Prevention and Treatment of Respiratory Syncytial Virus Infection, since there are currently no specific antiviral drugs for RSV infection, clinical management mainly consists of symptomatic supportive treatment such as oxygen therapy and fluid replacement as appropriate based on the individual condition of the infected person. This shows that the clinical need in the field of RSV infection treatment remains far from being met. GPN01564 is an important product reserve of the Group's anti-infection innovation platform within the respiratory and critical care segment, and together with the segment's marketed innovative products, it builds a synergistic product portfolio, forming a closed-loop management system covering the entire airway and full cycle of the respiratory segment: the novel compound nasal spray Leitling covers upper airway inflammation such as allergic rhinitis; the innovative inhaled preparations for asthma treatment Enzhuorun Bishihai Le and Enmingrun Bishihai Le are deeply engaged in the long-term control of lower airway chronic diseases such as asthma; and GPN01564 fills the gap in RSV-specific antiviral treatment, driving the platform's upgrade from a cluster of airway chronic disease products to a systemic respiratory treatment system. The respiratory and critical care field is one of the Group's core strategic areas, with marketed products covering multiple indications such as rhinitis, bronchitis, pneumonia, asthma and chronic obstructive pulmonary disease, among which the core product Qienuo is a sole variety in China and has been recommended by multiple guidelines and expert consensuses. On the payment side, Leitling was included for the first time this year in the National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2026) (the National Medical Insurance Drug Catalogue), and Enzhuorun Bishihai Le and Enmingrun Bishihai Le were successfully renewed in the National Medical Insurance Drug Catalogue, which helps improve patient access to medication and accelerate market penetration. GPN01564 is a globally innovative drug independently developed by the Group relying on its self-built anti-infection innovation platform. With the Wuhan Optics Valley International R&D Center as its core, the platform has built a global anti-infection innovative R&D network covering the entire chain from "early discovery process development clinical translation." The R&D center has a floor area of more than 13,000 square meters and is equipped with internationally advanced scientific research equipment, capable of conducting research and development of small-molecule drugs, peptide drugs and high-end complex dosage form drugs, and has established distinctive laboratories for new drug pharmacodynamic evaluation, process thermal safety evaluation, crystallization technology and continuous flow process research. The platform holds the qualifications of a national-level enterprise technology center and provincial-level or above R&D innovation technology platforms, and has established a national postdoctoral research workstation. With the mission of "tackling major infectious diseases," the platform has laid out high-burden tracks in the field of respiratory viral infections, including RSV, sepsis, acute respiratory distress syndrome (ARDS), influenza, herpes virus, novel coronavirus infection and Gram-negative bacteria, directly addressing unmet clinical needs; it has built a continuous project pipeline from candidate molecule discovery, preclinical research and registration filing to the clinical development stage, which is being advanced in an orderly manner. In the future, the Group will continue to strengthen strategic investment in this platform, focusing on enhancing the level of original innovation, molecular discovery efficiency and clinical translation capability, accelerating the platform's upgrade toward a systemic treatment system, and comprehensively supporting the long-term high-quality development of the anti-infection field within the respiratory and critical care segment. The Group has always attached great importance to the research and development of innovative products and advanced technologies. With patient needs at the core and technological innovation as the driver, and targeting unmet clinical needs, the Group has increased investment in globally innovative products and advanced technologies, enriched and improved its product pipeline and industrial layout, and adopted the strategy of "global operational layout, dual-circulation business development" to form a new pattern of mutually reinforcing and interconnected domestic and international dual circulation development. This fully leverages the Group's industrial advantages and R&D strength to rapidly bring technologically innovative products to market, providing patients worldwide with more advanced and more diverse treatment options.